Journal Club: Biologics and Potential for Immune Modulation in Chronic Obstructive Lung Disease.
作者信息
Mkorombindo Takudzwa, Balkissoon Ron
机构信息
Lung Health Center, Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama, Birmingham, Alabama, United States.
Denver, Colorado.
出版信息
Chronic Obstr Pulm Dis. 2022 Apr 29;9(2):285-297. doi: 10.15326/jcopdf.2022.0318.
Abstract
摘要
相似文献
1
Journal Club: Biologics and Potential for Immune Modulation in Chronic Obstructive Lung Disease.期刊俱乐部：生物制剂与慢性阻塞性肺疾病免疫调节的潜力
Chronic Obstr Pulm Dis. 2022 Apr 29;9(2):285-297. doi: 10.15326/jcopdf.2022.0318.
2
Journal Club-COPD2020 Update. Global Initiative for Chronic Obstructive Lung Disease 2020 Report and the Special Edition, Moving to a New Definition for COPD: "COPDGene 2019".期刊俱乐部-慢性阻塞性肺疾病2020年更新。慢性阻塞性肺疾病全球倡议2020年报告及特刊，转向慢性阻塞性肺疾病的新定义：“慢性阻塞性肺疾病基因2019”
Chronic Obstr Pulm Dis. 2019 Oct 23;6(4):64-72. doi: 10.15326/jcopdf.7.1.2020.0133.
3
Angiotensin-converting enzyme 2 in peripheral lung club cells modulates the susceptibility to SARS-CoV-2 in chronic obstructive pulmonary disease.外周肺 club 细胞中的血管紧张素转换酶 2 调节慢性阻塞性肺疾病对 SARS-CoV-2 的易感性。
Am J Physiol Lung Cell Mol Physiol. 2022 May 1;322(5):L712-L721. doi: 10.1152/ajplung.00305.2021. Epub 2022 Mar 23.
4
T2 Biologics for Chronic Obstructive Pulmonary Disease.T2 生物制剂治疗慢性阻塞性肺疾病。
J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1405-1416. doi: 10.1016/j.jaip.2019.01.036.
5
Journal Club - Endobronchial Valve Bronchoscopic Lung Volume Reduction.期刊俱乐部 - 支气管内瓣膜支气管镜肺减容术
Chronic Obstr Pulm Dis. 2019 Jan 25;6(1):118-125. doi: 10.15326/jcopdf.6.1.2019.0126.
6
Recent advances in chronic obstructive pulmonary disease pathogenesis: from disease mechanisms to precision medicine.慢性阻塞性肺疾病发病机制的最新进展：从疾病机制到精准医学。
J Pathol. 2020 Apr;250(5):624-635. doi: 10.1002/path.5364. Epub 2019 Dec 3.
7
Club Cell Protein 16 (CC16) Augmentation: A Potential Disease-modifying Approach for Chronic Obstructive Pulmonary Disease (COPD).克拉拉细胞蛋白16（CC16）增强：一种慢性阻塞性肺疾病（COPD）潜在的疾病修饰方法。
Expert Opin Ther Targets. 2016 Jul;20(7):869-83. doi: 10.1517/14728222.2016.1139084. Epub 2016 Feb 11.
8
Journal Club - Asthma/Chronic Obstructive Pulmonary Disease Overlap: Fact or Fiction?期刊俱乐部 - 哮喘/慢性阻塞性肺疾病重叠：事实还是虚构？
Chronic Obstr Pulm Dis. 2018 Oct 17;5(4):341-350. doi: 10.15326/jcopdf.5.4.2018.0162.
9
Immune-Modulation in Chronic Obstructive Pulmonary Disease: Current Concepts and Future Strategies.慢性阻塞性肺疾病中的免疫调节：当前概念与未来策略
Respiration. 2020;99(7):550-565. doi: 10.1159/000502261. Epub 2019 Sep 3.
10
Journal Club: COPD and Oxygen Therapy.期刊俱乐部：慢性阻塞性肺疾病与氧疗
Chronic Obstr Pulm Dis. 2017 Jan 5;4(1):71-75. doi: 10.15326/jcopdf.4.1.2016.0181.
本文引用的文献
1
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.特泽泊鲁单抗治疗口服糖皮质激素依赖型哮喘成人患者的口服糖皮质激素节省效果评估（SOURCE）：一项随机、安慰剂对照、3 期研究。
Lancet Respir Med. 2022 Jul;10(7):650-660. doi: 10.1016/S2213-2600(21)00537-3. Epub 2022 Mar 29.
2
Deciphering Respiratory-Virus-Associated Interferon Signaling in COPD Airway Epithelium.解析 COPD 气道上皮中与呼吸道病毒相关的干扰素信号通路。
Medicina (Kaunas). 2022 Jan 13;58(1):121. doi: 10.3390/medicina58010121.
3
Association of Intestinal Microbial Dysbiosis With Chronic Obstructive Pulmonary Disease.肠道微生物群失调与慢性阻塞性肺疾病的关联
Cureus. 2021 Nov 7;13(11):e19343. doi: 10.7759/cureus.19343. eCollection 2021 Nov.
4
Waiting for Actionable Evidence: Roflumilast or Azithromycin?等待可采取行动的证据：罗氟司特还是阿奇霉素？
Chronic Obstr Pulm Dis. 2022 Jan 27;9(1):1-3. doi: 10.15326/jcopdf.2021.0272.
5
Gut microbiota dysbiosis contributes to the development of chronic obstructive pulmonary disease.肠道微生物失调导致慢性阻塞性肺疾病的发生。
Respir Res. 2021 Oct 25;22(1):274. doi: 10.1186/s12931-021-01872-z.
6
Inhaled Corticosteroids and the Lung Microbiome in COPD.慢性阻塞性肺疾病中吸入性糖皮质激素与肺部微生物群
Biomedicines. 2021 Sep 24;9(10):1312. doi: 10.3390/biomedicines9101312.
7
The Use of Inhaled Corticosteroids for Patients with COPD Who Continue to Smoke Cigarettes: An Evaluation of Current Practice.吸入性糖皮质激素在持续吸烟的慢性阻塞性肺疾病患者中的应用：当前实践评估
Am J Med. 2022 Mar;135(3):302-312. doi: 10.1016/j.amjmed.2021.09.006. Epub 2021 Oct 14.
8
Inhaled corticosteroids in COPD: risk and benefits.慢性阻塞性肺疾病中吸入性糖皮质激素：风险与益处
Thorax. 2022 Jun;77(6):530-531. doi: 10.1136/thoraxjnl-2021-217930. Epub 2021 Sep 23.
9
Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab.重症哮喘生物治疗的分子靶点：聚焦于贝那利珠单抗和替泽佩单抗。
Life (Basel). 2021 Jul 26;11(8):744. doi: 10.3390/life11080744.
10
Obesity-Induced Dysbiosis Exacerbates IFN-γ Production and Pulmonary Inflammation in the Infection.肥胖诱导的菌群失调会加剧感染过程中的γ-干扰素产生及肺部炎症。
Cells. 2021 Jul 8;10(7):1732. doi: 10.3390/cells10071732.
Zotero 插件